Background: Statin drugs (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) reduce the level of cholesterol by inhibiting the synthesis of mevalonate, an intermediary in the cholesterol biosynthetic pathway. Use of statin drugs has been associated with a variety of skeletal muscle-related complaints. Coenzyme Q 10 (CoQ 10 ), a component of the mitochondrial respiratory chain, is also synthesized from mevalonate, and decreased muscle CoQ 10 concentration may have a role in the pathogenesis of statin drug-related myopathy.
S
TATIN DRUGS (3-HYDROXY-3-methylglutaryl coenzyme A reductase inhibitors) are widely prescribed drugs that reduce blood cholesterol levels by inhibiting the synthesis of mevalonate, a critical intermediary in the cholesterol pathway. Statin drug therapy has been associated with a variety of muscle complaints, ranging from myalgia and cramps to exercise intolerance, weakness, and, occasionally, acute muscle breakdown with myoglobinuria.
1,2 Serum creatine kinase (CK) levels are elevated in all of these conditions. 2 It is curious that muscle symptoms and high serum CK levels often persist even after statin drug withdrawal. 2 Coenzyme Q 10 (CoQ 10 ), a lipophilic component of the electron transport chain, transfers electrons from complexes I and II to complex III, and it also is an antioxidant and a membrane stabilizer. While it was clearly shown that atorvastatin decreases the concentration of blood CoQ 10 in patients with hyperchlolesterolemia, 3 a similar effect of statin drugs on muscle CoQ 10 has not been documented. In addition, studies in rat and in human muscle cultures suggested that statin drugs induce apoptosis but not CoQ 10 deficiency. 4 To investigate a possible correlation between statin drug-related myopathy and CoQ 10 deficiency, we studied muscle biopsy specimens from 18 patients with statin drug-related muscle symptoms or high serum CK levels. We correlated muscle structure with CoQ 10 concentration, respiratory chain complex III activity, and evidence of apoptosis, using the TUNEL (terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling) assay and immunohistochemistry with antibodies against caspase-3, Bax, and Bcl-2).
METHODS

PATIENTS
We examined 18 patients with hypercholesterolemia (8 men, 10 women), aged 31 to 76 years, who were receiving statin drugs. Eight of 18 patients had both weakness and myalgia, 4 patients had only weakness, 3 patients had only myalgia, and 5 patients reported cramps ( Table 1 Six patients were receiving simvastatin; 5, cerivastatin; 3, atorvastatin; and 1, rosuvastatin, at dosages of 5 mg/d (1 patient), 10 mg/d (9 patients), or 20 mg/d (5 patients). Neither type of statin drug nor dosage was known in 3 patients. Electromyography was performed in 15 patients and demonstrated myopathic changes in 6 patients, neuropathic changes in 3 patients, and normal findings in 6 patients ( Table 1) .
MORPHOLOGY AND BIOCHEMISTRY
Muscle histochemistry and measurements of respiratory chain enzymes in muscle extracts were performed using described techniques. 5, 6 Immunohistochemical reactions for both proapoptotic (TUNEL, Bax, and caspase-3) and antiapoptotic (Bcl-2) markers were carried out in serial cryostat cross sections. 7 The TUNEL assay was performed according to the manufacturer's instructions (In Situ Cell Death Detection Kit; Roche Applied Science, Mannheim, Germany). As for the proapoptotic and antiapoptotic markers (Santa Cruz Biotechnology, Santa Cruz, Calif ), anti-Bax was a rabbit polyclonal antibody raised against the amino terminus of human Bax, anti-caspase-3 was a goat polyclonal antibody raised against the amino terminus of the human caspase-3 p11 subunit, and anti-Bcl-2 was a mouse monoclonal antibody obtained by fusing myeloma cells with spleen cells from an immunized mouse. As secondary antibody, we used antimouse IgG. The reactions were developed with 3,3Ј-diaminobenzidine using the avidin-biotin compleximmunoperoxidase vector amplified system (Vectastain Elite ABC Kit; Vector Laboratories, Burlingame, Calif ), as previously described. 7 Coenzyme Q 10 was extracted from muscle (50 µL of muscle homogenate and 950 µL of ice-cold 1-propanol) by vortex mixing in a microcentrifuge tube for 2 minutes; after centrifugation at 14 000 rpm for 10 minutes at 4°C, 30 µL of clear supernatant was injected directly into the high-performance liquid chromatographic system. High-performance liquid chromatographic analyses were performed using a reverse-phase isocratic system, as previously described. 8 
RESULTS
Muscle structure was normal or showed mild myopathic changes in 14 patients. In 2 patients (patients 7 and 8 [ Table 2 ]), there were a few necrotic and vacuolated fibers. Only 2 patients demonstrated some evidence of mitochondrial dysfunction: 5 cytochrome c oxidase-negative ragged red fibers were seen in the biopsy specimen from 61-year-old patient 10, and 2 cytochrome c oxidase-negative fibers were seen in the biopsy specimen from 63-year-old patient 11 ( Table 2) .
The levels of muscle CoQ 10 in our patients as a group were not significantly different from those in control subjects (median values, 29.5 µg/g in patients vs 32.0 in 118 controls; PϾ.05, Mann-Whitney rank sum test). However, muscle CoQ 10 concentration was below 2 SDs of the normal mean in 3 patients and below 1 SD in 7 patients (10 [56%] of 18 patients). In the remaining 8 patients the concentration of muscle CoQ 10 was normal (±1 SD of the mean) in 4 patients and increased (Ͼ2 SDs) in 4 Figure) . There was no clear correlation between muscle structure and CoQ 10 concentration, but the 2 patients (patients 10 and 11) with a few ragged red fibers or cytochrome c oxidase-negative fibers had CoQ 10 levels at or below 1 SD of the mean. One of the 2 (patient 10) also had the highest serum CK levels. Complex III activity was normal in all patients. The TUNEL assay and immunohistochemical studies with antibodies against Bax, Bcl−2, and caspase−3 were performed in the 11 patients from whom enough tissue was available; all of these tests yielded negative results in all 11 patients.
COMMENT
In developed countries, statin drugs are among the most frequently administered drugs used to lower the blood cholesterol level and prevent cardiovascular disease and stroke. Usually they are well tolerated and safe, but in fewer than 1% of patients they cause muscle problems, usually exercise-related myalgia and cramps, less commonly fixed weakness, and occasionally acute muscle breakdown (rhabdomyolysis) and myoglobinuria. 2 The incidence of myopathy seems to be similar for different statin drugs.
The pathogenesis of statin drug-related myopathy is unknown. 9, 10 An attractive hypothesis is that muscle symptoms may be due to a partial defect of CoQ 10 , because CoQ 10 and cholesterol share a common biosynthetic pathway that is inhibited by statin drugs. This concept is supported by findings in blood samples from patients with hypercholesterolemia, in whom CoQ 10 concentration decreased to 50% of baseline values after 30 days of treatment with atorvastatin, 3 although the dosage of statin (80 mg/d) was considerably higher than in our patients (5−20 mg/d). Indirect support for this hypothesis comes from knowledge that severe, and presumably primary, muscle CoQ 10 deficiency causes mitochondrial myopathic changes with exercise intolerance and recurrent myoglobinuria.
11−15 Less severe muscle CoQ 10 deficiency is associated with a syndrome dominated by cerebellar ataxia but often accompanied by muscle weakness. 16−18 In patients with ataxic CoQ 10 deficiency muscle biopsy tissue is usually normal or nonspecifically myopathic and the activity of complex III of the respiratory chain is inconsistently decreased.
To shed some light on the role of CoQ 10 in the pathogenesis of statin drug-related myopathy we studied the muscle biopsy specimens from 18 patients given standard doses of statin drugs to treat hypercholesterolemia with reports of muscle pain, cramps, and weakness (16 patients) or with increased levels of serum CK in the absence of symptoms (2 patients). We found decreased muscle CoQ 10 concentration in 10 patients (56%), but the decrease was slight (Ͻ1 SD of the normal mean) in 7 patients (70%) and severe (Ͻ2 SDs) in only 3 patients (30%). None of the 3 patients (patients 3, 16, and 17) with the lowest CoQ 10 concentrations had abnormal muscle structure or biochemical changes. Conversely, the 2 patients (patients 10 and 11) with some morphologic evidence of mitochondrial dysfunction had only modest decreases in muscle CoQ 10 concentrations. In addition, both patients were older than 60 years, which raises the possibility that the few ragged red fibers and cytochrome c oxidase-negative fibers in their biopsy specimens may have been related to aging rather than to CoQ 10 deficiency. The increased muscle concentrations of CoQ 10 in 4 patients (patients 6, 7, 8, and 14) are difficult to explain, unless these patients were taking vitamin supplements containing CoQ 10 , a possibility we could not exclude with certainty.
Because the muscle biopsy specimens from 2 young brothers with myopathic CoQ 10 deficiency showed florid apoptosis, 13 and studies in rat and in human muscle cultures exposed to statin drugs had also shown activation of apoptotic pathways (without CoQ 10 deficiency), 4 we looked for evidence of apoptosis in our patients, but found none.
In summary, our data suggest that statin drugs may decrease the concentration of CoQ 10 in muscle to a modest extent in some patients. Although these data do not support a pathogenic role of CoQ 10 deficiency in statin drug-related myopathy, it may be prudent to advocate that patients with statin drug-related myopathy be given oral CoQ 10 supplementation. 
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